A new real-world analysis by Omada Health finds that many members maintain weight loss long after discontinuing GLP-1 medication, according to the company.
The retrospective study monitored 816 members enrolled in Omada’s GLP-1 Care Track, tracking weight change at 6, 9, and 12 months post-discontinuation. The company said that participants exhibited minimal average weight change: 0.03% at six months, 0.6% at nine months, and 0.8% at one year. The company claims this compares favorably with weight regain of 11–12% typically seen in clinical trials, where participants often lack ongoing lifestyle support.
Omada said that 63% of members either maintained weight loss or continued losing weight at the one-year mark. The company attributes these outcomes to continuous behavioral support, connected devices, AI-enhanced digital tools, and care teams that emphasize muscle preservation through activity guidance.
Omada noted that the findings challenge industry assumptions about unavoidable weight regain after stopping GLP-1 treatments. The analysis relied on pharmacy claims data and was conducted as part of the company’s Omada Insights Lab ANSWERS initiative, which examines real-world outcomes from its behavioral weight-health programs.
If confirmed by independent research, the results may inform how payers, employers, and care providers support individuals transitioning off GLP-1 medications.
